Condition: Ovarian Cancer · Malignant Neoplasm of Uterus · Sponsor: Icahn School of Medicine at Mount Sinai
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
This description comes directly from the study's public registry record.
Amy Tiersten, MD · (212) 241-3300 · amy.tiersten@mssm.edu
Melanie Kier, MD · melanie.kier@mssm.edu
Always discuss trial participation with your own doctor first.
| Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06040970